Souza CA, Pagnano KB, Bendit I, Conchon M, Freitas CM, Coelho AM, Funke VA, Bernardo WM PICO 14 Does adherence to Imatinib treatment have prognostic impact? (Leukemia, Myelogenous, Chronic, BCR-ABL Positive OR Leukemia, Myeloid, Philadelphia-Positive OR Leukemia, Granulocytic, Chronic OR Myeloid Leukemia, Chronic OR Chronic Myeloid Leukemia OR Leukemia, Myelocytic, Chronic OR Chronic Myelocytic Leukemia OR Leukemia, Myelogenous, Chronic OR Myelogenous Leukemia, Ph1-Positive OR Leukemia, Myeloid, Ph1 Positive OR Myelogenous Leukemia, Chronic OR Myeloid Leukemia, Philadelphia-Positive OR Granulocytic Leukemia, Chronic) AND imatinib AND Prognosis AND (Adherence OR Compliance) PICO 15 Are prior cytogenetic response with Imatinib and performance status prognostic factors for response to second-line tyrosine kinase inhibitors in patients resistant to Imatinib? (Leukemia, Myelogenous, Chronic, BCR-ABL Positive OR Leukemia, Myeloid, Philadelphia-Positive OR Leukemia, Granulocytic, Chronic OR Myeloid Leukemia, Chronic OR Chronic Myeloid Leukemia OR Leukemia, Myelocytic, Chronic OR Chronic Myelocytic Leukemia OR Leukemia, Myelogenous, Chronic OR Myelogenous Leukemia, Ph1-Positive OR Leukemia, Myeloid, Ph1 Positive OR Myelogenous Leukemia, Chronic OR Myeloid Leukemia, Philadelphia-Positive OR Granulocytic Leukemia, Chronic) AND (Cytogenetic Analysis OR Cytogenetic* OR performance status OR Karnofsky Performance Status) AND Imatinibe AND (Nilotinib OR Dasatinibe) AND ((sensitiv*[Title/ Abstract] OR sensitivity and specificity[MeSH Terms] OR diagnos*[Title/Abstract]ORdiagnosis[MeSH:noexp]ORdiagnostic *[MeSH:noexp] OR diagnosis, differential[MeSH:noexp] OR diagnosis[Subheading:noexp]) OR (prognos*[Title/Abstract] OR (first[Title/Abstract] AND episode[Title/Abstract]) OR cohort[Title/Abstract])) OR (evaluation study OR comparative study OR epidemiologic methods)) PICO 16 When is it necessary to make an analysis of BCR-ABL mutations in CML patients under treatment with tyrosine kinase inhibitors? (Leukemia, Myelogenous, Chronic, BCR-ABL Positive OR Leukemia, Myeloid, Philadelphia-Positive OR Leukemia, Granulocytic, Chronic OR Myeloid Leukemia, Chronic OR Chronic Myeloid Leukemia OR Leukemia, Myelocytic, Chronic OR Chronic Myelocytic Leukemia OR Leukemia, Myelogenous, Chronic OR Myelogenous Leukemia, Ph1-Positive OR Leukemia, Myeloid, Ph1 Positive OR Myelogenous Leukemia, Chronic OR Myeloid Leukemia, Philadelphia-Positive OR Granulocytic Leukemia, Chronic) AND (Fusion Proteins, bcr-abl OR BCR-ABL OR BCR/ ABL) AND (Protein Kinase Inhibitors OR crizotinib OR Cyclin- Dependent Kinase Inhibitor p15 OR Cyclin-Dependent Kinase Inhibitor p18 OR Cyclin-Dependent Kinase Inhibitor p19 OR Cyclin-Dependent Kinase Inhibitor p21 OR Cyclin-Dependent Kinase Inhibitor p27 OR Cyclin-Dependent Kinase Inhibitor p57 OR Cyclin-Dependent Kinase Inhibitor Proteins OR dasatinib OR erlotinib OR fasudil OR flavopiridol OR gefitinib OR Genistein OR imatinib OR lapatinib OR roscovitine OR sorafenib OR vatalanib) PICO 17 Does the diagnosis of mutations guide the choice of treatment in imatinib-resistant patients? ((((Leukemia, Myelogenous, Chronic, BCR-ABL Positive OR Leukemia, Myeloid, Philadelphia-Positive OR Leukemia, Granulocytic, Chronic OR Myeloid Leukemia, Chronic OR Chronic Myeloid Leukemia OR Leukemia, Myelocytic, Chronic OR Chronic Myelocytic Leukemia OR Leukemia, Myelogenous, Chronic OR Myelogenous Leukemia, Ph1-Positive OR Leukemia, Myeloid, Ph1 Positive OR Myelogenous Leukemia, Chronic OR Myeloid Leukemia, Philadelphia-Positive OR Granulocytic Leukemia, Chronic))) AND (((Fusion Proteins, bcr-abl)) OR (Mutation*))) AND (((nilotinib OR dasatinib)) OR (bone marrow transplantation)) PICO 18 How should monitoring of CML patients taking tyrosine kinase inhibitors be performed? (Leukemia, Myelogenous, Chronic, BCR-ABL Positive OR Leukemia, Myeloid, Philadelphia-Positive OR Leukemia, Granulocytic, Chronic OR Myeloid Leukemia, Chronic OR Chronic Myeloid Leukemia OR Leukemia, Myelocytic, Chronic OR Chronic Myelocytic Leukemia OR Leukemia, Myelogenous, Chronic OR Myelogenous Leukemia, Ph1-Positive OR Leukemia, Myeloid, Ph1 Positive OR Myelogenous Leukemia, Chronic OR Myeloid Leukemia, Philadelphia-Positive OR Granulocytic Leukemia, Chronic) AND (Protein Kinase Inhibitors OR Imatinib OR Nilotinib OR Dasatinib) AND (Blood Cell Count OR Cytogenetics OR Polymerase Chain Reaction OR Mutation* OR In Situ Hybridization, Fluorescence) AND monitor* PICO 19 When should bone marrow transplantation be indicated for CML patients? (Leukemia, Myelogenous, Chronic, BCR-ABL Positive OR Leukemia, Myeloid, Philadelphia-Positive OR Leukemia, Granulocytic, Chronic OR Myeloid Leukemia, Chronic OR Chronic Myeloid Leukemia OR Leukemia, Myelocytic, Chronic OR Chronic Myelocytic Leukemia OR Leukemia, Myelogenous, Chronic OR Myelogenous Leukemia, Ph1-Positive OR Leukemia, Myeloid, Ph1 Positive OR Myelogenous Leukemia, Chronic OR Myeloid Leukemia, Philadelphia-Positive OR Granulocytic Leukemia, Chronic) AND BONE MARROW TRANSPLANTATION AND (Therapy/broad[filter] OR Comparative study) xxx 382 Rev Bras Hematol Hemoter. 2012;34(5):367-82